Camazepam

Camazepam
Clinical data
Pregnancy; category	?;
Routes of; administration	Oral
ATC code	N05BA15 (WHO) ;
Legal status
Legal status	BR: Class B1 (Psychoactive drugs); CA: Schedule IV; DE: Anlage III (Special prescription form required); UK: Class C; US: Schedule IV;
Pharmacokinetic data
Bioavailability	90%
Metabolism	Hepatic
Elimination half-life	6,4-10,5 hours
Excretion	Renal
Identifiers
	IUPAC name 7-chloro-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl N,N-dimethylcarbamate;
CAS Number	36104-80-0 ;
PubChem CID	37367;
DrugBank	DB01489 ;
ChemSpider	34285 ;
UNII	HZ3XRH03C3;
KEGG	D07315 ;
ChEMBL	ChEMBL1095282 ;
CompTox Dashboard (EPA)	DTXSID50865803 ;
ECHA InfoCard	100.048.046
Chemical and physical data
Formula	C19H18ClN3O3
Molar mass	371.82 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES ClC1=CC2=C(C=C1)N(C)C(C(N=C2C3=CC=CC=C3)OC(N(C)C)=O)=O;
	InChI InChI=1S/C19H18ClN3O3/c1-22(2)19(25)26-17-18(24)23(3)15-10-9-13(20)11-14(15)16(21-17)12-7-5-4-6-8-12/h4-11,17H,1-3H3 ; Key:PXBVEXGRHZFEOF-UHFFFAOYSA-N ;
	(verify)

Camazepam^[2] is a benzodiazepine psychoactive drug, marketed under the brand names Albego, Limpidon and Paxor. It is the dimethyl carbamate ester of temazepam, a metabolite of diazepam.^[3] While it possesses anxiolytic, anticonvulsant, skeletal muscle relaxant and hypnotic properties^[4] it differs from other benzodiazepines in that its anxiolytic properties are particularly prominent but has comparatively limited anticonvulsant, hypnotic and skeletal muscle relaxant properties.

^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
^ DE 2142181, "1,4 Benzodiazepine derivatives and process for their production", issued 23 December 1976, assigned to Siphar S A , Lugano (Schweiz).
^ Tammaro A, Picceo MT, Gemmellaro P, Bonaccorso O (1977). "Camazepam versus placebo. A double-blind clinical study on geriatric patients suffering from psychic complaints. Short Communication". Arzneimittel-Forschung. 27 (11): 2177–2178. PMID 23793.
^ Lu XL, Yang SK (April 1994). "Enantiomer resolution of camazepam and its derivatives and enantioselective metabolism of camazepam by human liver microsomes". Journal of Chromatography A. 666 (1–2): 249–257. doi:10.1016/0021-9673(94)80387-0. PMID 7911374.

Clinical data


Pregnancy category	?
Routes of administration	Oral
ATC code	N05BA15 (WHO)
Legal status
Legal status	BR: Class B1 (Psychoactive drugs)^[1] CA: Schedule IV DE: Anlage III (Special prescription form required) UK: Class C US: Schedule IV
Pharmacokinetic data
Bioavailability	90%
Metabolism	Hepatic
Elimination half-life	6,4-10,5 hours
Excretion	Renal
Identifiers
IUPAC name 7-chloro-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl N,N-dimethylcarbamate
CAS Number	36104-80-0^Y
PubChem CID	37367
DrugBank	DB01489^Y
ChemSpider	34285^Y
UNII	HZ3XRH03C3
KEGG	D07315^Y
ChEMBL	ChEMBL1095282^Y
CompTox Dashboard (EPA)	DTXSID50865803
ECHA InfoCard	100.048.046
Chemical and physical data
Formula	C₁₉H₁₈ClN₃O₃
Molar mass	371.82 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES ClC1=CC2=C(C=C1)N(C)C(C(N=C2C3=CC=CC=C3)OC(N(C)C)=O)=O
InChI InChI=1S/C19H18ClN3O3/c1-22(2)19(25)26-17-18(24)23(3)15-10-9-13(20)11-14(15)16(21-17)12-7-5-4-6-8-12/h4-11,17H,1-3H3^Y Key:PXBVEXGRHZFEOF-UHFFFAOYSA-N^Y
(verify)